Cisplatin cas 15663-27-1

Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis. Cisplatin (30 mM) treated for 6 h induces an apparent activation of Erk in HeLa cells, which is sustained over the following 14 h period. Cisplatin also shows an effective antineoplastic activity by inducing tumor cells death. Cisplatin displays ability to cause renal proximal tubular cell (RPTC) apoptosis, causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively. Cisplatin (800 μM) causes typical features of necrosis of RPTC after treatment for 4 hr.

Related Prodcuts:

Gemcitabine HCL; Bleomycin Sulfate; Temozolomide; Carmustine; CX-5461; Fludarabine Phosphate; Nelarabine; Cladribine; Trifluridine; Daptomycin

[1] Siddik ZH. Oncogene, 2003, 22(47), 7265-7279.

[2] Cummings BS, et al. J Pharmacol Exp Ther, 2002, 302(1):8-17.

[3] Lieberthal W, et al. Am J Physiol, 1996, 270(4 Pt 2), F700-708.